title: Prolonged esophagitis after primary dysfunction of the pyloric sphincter in the rat and therapeutic potential of the gastric pentadecapeptide BPC 157.
abstract: Seven or fourteen days or twelve months after suturing one tube into the pyloric sphincter (removed by peristalsis by the seventh day), rats exhibit prolonged esophagitis with a constantly lowered pressure not only in the pyloric, but also in the lower esophageal sphincter and a failure of both sphincters. Throughout the esophagitis experiment, gastric pentadecapeptide BPC 157 (PL 14736) is given intraperitoneally once a day (10 microg/kg, 10 ng/kg, last application 24 h before assessment), or continuously in drinking water at 0.16 microg/ml, 0.16 ng/ml (12 ml/rat per day), or directly into the stomach 5 min before pressure assessment (a water manometer connected to the drainage port of a Foley catheter implanted into the stomach either through an esophageal or duodenal incision). This treatment alleviates i) the esophagitis (macroscopically and microscopically, at either region or interval), ii) the pressure in the pyloric sphincter, and iii) the pressure in the lower esophageal sphincter (cmH2O). In the normal rats it increases lower esophageal sphincter pressure, but decreases the pyloric sphincter pressure. Ranitidine, given using the same protocol (50 mg/kg, intraperitoneally, once daily; 0.83 mg/ml in drinking water; 50 mg/kg directly into the stomach) does not have an effect in either rats with esophagitis or in normal rats.
authors: Department of Pharmacology, Medical School, University of Zagreb, Croatia.
authors: Ivan
authors: I
authors: Dobric
authors: Petar
authors: P
authors: Drvis
authors: Igor
authors: I
authors: Petrovic
authors: Drazen
authors: D
authors: Shejbal
authors: Luka
authors: L
authors: Brcic
authors: Alenka Boban
authors: AB
authors: Blagaic
authors: Lovorka
authors: L
authors: Batelja
authors: Marko
authors: M
authors: Sever
authors: Neven
authors: N
authors: Kokic
authors: Ante
authors: A
authors: Tonkic
authors: Ivan
authors: I
authors: Zoricic
authors: Sandro
authors: S
authors: Mise
authors: Mario
authors: M
authors: Staresinic
authors: Bozo
authors: B
authors: Radic
authors: Ana
authors: A
authors: Jakir
authors: Jaksa
authors: J
authors: Babel
authors: Spomenko
authors: S
authors: Ilic
authors: Tihomir
authors: T
authors: Vuksic
authors: Ivan
authors: I
authors: Jelic
authors: Tomislav
authors: T
authors: Anic
authors: Sven
authors: S
authors: Seiwerth
authors: Predrag
authors: P
authors: Sikiric
mesh_terms: D000818:Animals; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D049630:Esophageal Sphincter, Lower / Q000187:drug effects / Q000293:injuries / Q000503:physiopathology; D004941:Esophagitis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D007441:Intubation, Gastrointestinal; D009129:Muscle Tonus / Q000187:drug effects; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011506:Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D011708:Pylorus / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D006635:Histamine H2 Antagonists; D010446:Peptide Fragments; D011506:Proteins; D011899:Ranitidine; C083833:BPC 157